---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies"
date: 2026-02-05 18:58:17 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-04245
original_published: 2022-03-01 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 01, 2022 00:00 UTC
**Document Number:** 2022-04245

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Syncopation Life Sciences Inc., ("Syncopation"), located in Palo Alto, California.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/01/2022-04245/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-chimeric)
- API: https://www.federalregister.gov/api/v1/documents/2022-04245

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
